{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:02Z","timestamp":1794270122757,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470571"],"award-info":[{"award-number":["82470571"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270580"],"award-info":[{"award-number":["82270580"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107948","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:22:16Z","timestamp":1785565336000},"page":"107948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vonoprazan-based dual and quadruple therapy with varying duration for Helicobacter pylori eradication: A multicenter, randomised controlled trial"],"prefix":"10.1016","volume":"67","author":[{"given":"Kunping","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leina","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangshang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-3269","authenticated-orcid":false,"given":"Qingzhou","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7042-9695","authenticated-orcid":false,"given":"Yueyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107948_bib0001","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0003","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1038\/s41591-024-03153-w","article-title":"Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial","volume":"30","author":"Pan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12738","article-title":"Review - Helicobacter pylori and non-malignant upper gastro-intestinal diseases","volume":"25","author":"Schulz","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107325","article-title":"Antibiotic resistance of Helicobacter pylori in Mainland China: a focus on geographic differences through systematic review and meta-analysis","volume":"64","author":"Zeng","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0006","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrgastro.2010.210","article-title":"Optimal therapy for Helicobacter pylori infections","volume":"8","author":"Rimbara","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13048","article-title":"Clarifying varied Helicobacter pylori eradication therapies: a comprehensive review","volume":"29","author":"Wu","year":"2024","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0009","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0010","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.14309\/ajg.0000000000003183","article-title":"When subtraction wins, what are the considerations for addition in Helicobacter pylori eradication?","volume":"120","author":"Kong","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0011","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.14309\/ajg.0000000000002298","article-title":"It is time for a paradigm shift in design, execution, and publishing of comparative Helicobacter pylori treatment trials","volume":"118","author":"Graham","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70070","article-title":"Ten-day versus 14-day Vonoprazan and Amoxicillin dual therapy for the firstline eradication of Helicobacter pylori infection: a multicenter, randomized controlled trial","volume":"30","author":"Song","year":"2025","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0013","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.cgh.2024.01.022","article-title":"Efficacy and safety of Vonoprazan-amoxicillin dual regimen with varying dose and duration for Helicobacter pylori eradication: a multicenter, prospective, randomized study","volume":"22","author":"Peng","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.ijantimicag.2026.107948_bib0014","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1111\/jgh.16761","article-title":"Ten-day versus 14-day vonoprazan-amoxicillin high-dose dual therapy for Helicobacter pylori eradication in China: a multicenter, open-label, randomized study","volume":"39","author":"Lin","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13039","article-title":"Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: a systematic review and meta-analysis","volume":"29","author":"Du","year":"2024","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0016","article-title":"Seven-day versus 14-day Tegoprazan and tetracycline-containing quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomized, open-label","volume":"30","author":"Nan","year":"2025","journal-title":"Noninferiority Trial Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0017","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day Vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy","volume":"118","author":"Qian","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0019","doi-asserted-by":"crossref","first-page":"787","DOI":"10.14309\/ajg.0000000000003084","article-title":"Comparative efficacy and safety of potassium-competitive acid blocker-based dual, triple, and quadruple regimens for first-line Helicobacter pylori infection treatment: a systematic review and network meta-analysis","volume":"120","author":"Rokkas","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13150","article-title":"Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for first-line Helicobacter pylori eradication therapy: a systematic review and network meta-analysis","volume":"29","author":"Ouyang","year":"2024","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0021","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0022","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/1751-2980.13263","article-title":"High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: a systematic review and meta-analysis","volume":"25","author":"Wang","year":"2024","journal-title":"J Dig Dis"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13015","article-title":"Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: a systematic review and single arm meta-analysis","volume":"28","author":"Lin","year":"2023","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0024","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70082","article-title":"Tailored therapy guided by antibiotic genotypic resistances and CYP2C19 polymorphisms detected from fecal specimens for the first-line Helicobacter pylori eradication: a randomized controlled trial","volume":"30","author":"Suo","year":"2025","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0025","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1007\/s10620-024-08460-3","article-title":"Bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized clinical trial of 10 and 14 days","volume":"69","author":"Ding","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13144","article-title":"Optimal duration of bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"29","author":"Duan","year":"2024","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0027","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.14309\/ajg.0000000000001246","article-title":"Adverse event profile during the treatment of Helicobacter pylori: a real-world experience of 22,000 patients from the European registry on H. pylori management (Hp-EuReg)","volume":"116","author":"Nyssen","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0028","doi-asserted-by":"crossref","first-page":"778","DOI":"10.14309\/ajg.0000000000002641","article-title":"Is 10-day Vonoprazan with high-dose amoxicillin dual therapy efficient for eradicating Helicobacter pylori infection in China?","volume":"119","author":"Du","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiag059","article-title":"Comparative analysis of high-dose dual therapies in first-line Helicobacter pylori eradication: an inverse probability of treatment-weighted multicenter study","author":"Kong","year":"2026","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101116","article-title":"Eradication efficacy and the effect of vonoprazan-amoxicillin dual therapy on gut microbiota and antibiotic resistome","volume":"6","author":"Zhou","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0031","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan Triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0032","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12876","article-title":"Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: a single-center, prospective, open-label, randomized-controlled trial","volume":"27","author":"Shao","year":"2022","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12596","article-title":"High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial","volume":"24","author":"Yu","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0034","doi-asserted-by":"crossref","unstructured":"Huguet JM, Ferrer-Barcel\u00f3 L, Su\u00e1rez P, Barcelo-Cerda S, Sempere J, Saracino IM, et al. Role of compliance in Helicobacter pylori eradication treatment: results of the European Registry on H. pylori management. United Eur Gastroenterol J. 2024;12 :691-704; doi: 10.1002\/ueg2.12569.","DOI":"10.1002\/ueg2.12569"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0035","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1038\/s41467-025-61329-5","article-title":"The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations","volume":"16","author":"Higgins","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0036","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13115","article-title":"Artificial intelligence-generated patient education materials for Helicobacter pylori infection: a comparative analysis","volume":"29","author":"Zeng","year":"2024","journal-title":"Helicobacter"},{"key":"10.1016\/j.ijantimicag.2026.107948_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-16264-2","article-title":"Helicobacter pylori antimicrobial resistance and gene variants in Shandong Province","volume":"15","author":"Xue","year":"2025","journal-title":"Sci Rep"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:36:59Z","timestamp":1794267419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926002359"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107948","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vonoprazan-based dual and quadruple therapy with varying duration for Helicobacter pylori eradication: A multicenter, randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107948"}}